New Two-Step surgery could spare High-Risk women from early menopause
NCT ID NCT06726330
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new two-step preventive surgery for women with gene mutations (like BRCA1) that raise their risk of ovarian cancer. Instead of removing both ovaries and fallopian tubes at once, the first step removes only the fimbria (the end of the fallopian tube), and the ovaries are removed later, around menopause. The goal is to reduce cancer risk while delaying menopause and its side effects. About 1,100 women in France will choose either this new approach or the standard surgery, and they will be followed until age 70.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fimbriectomy followed by delayed oophorectomy (F-DO) surgical procedure
What this could lead to
If successful, this could offer a less drastic preventive option for women at high genetic risk of ovarian cancer, preserving ovarian function longer and delaying menopause.
What could go wrong
This is a non-randomized study, so results may be less definitive. The procedure is still being tested for effectiveness, and there is a small risk that cancer could still develop before the delayed ovary removal.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY PERITONEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Antoine Lacassagne
Nice, France
Contact
Contact
-
Centre François Baclesse
Caen, France
Contact
Contact
-
Centre Henri Becquerel
Rouen, France
Contact
Contact
-
Centre Hospitalier Universitaire Dijon Bourgogne
Dijon, France
-
Centre Hospitalier Universitaire de Lille
Lille, France
-
Centre Hospitalier de Valenciennes
Valenciennes, France, France
Contact
Contact
-
Centre Jean Perrin
Clermont-Ferrand, France
Contact
Contact
-
Centre Léon Bérard
Lyon, France, France
Contact
Contact
Contact
-
Centre Oscar Lambret
Lille, France
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre hospitalier universitaire Grenoble-Alpes
Grenoble, France
Contact
Contact
-
Clinique du Bois
Lille, France
Contact
Contact
-
Gustave Roussy
Paris, France
-
Hôpital Institut CURIE
Paris, France
Contact
Contact
-
Hôpital Simone Veil - CH de Troyes
Troyes, France
-
Hôpital Tenon AP-HP
Paris, France
Contact
Contact
-
Hôpital de Saint-Cloud
Saint-Cloud, France
Contact
Contact
-
Hôpital de la Pitié Salpêtrière - AP-HP
Paris, France
Contact
Contact
-
Hôpitaux Privés Rouennais
Rouen, France
Contact
Contact
-
Institut Bergonié
Bordeaux, France
Contact
Contact
-
Institut Godinot
Reims, France
Contact
Contact
-
Institut Paoli-Calmettes
Marseille, France
Contact
Contact
-
Institut de cancérologie de l'Ouest Centre René GAUDUCHEAU
Nantes, France
Contact
Contact
Contact
-
Institut universitaire du cancer de Toulouse
Toulouse, France, France
Contact
Contact